Article
CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
International journal of hematology - 1 Jul 2018
Watanabe Junichi, Sato Ken, Osawa Yukiko, Horiuchi Toshikatsu, Kato Shoichiro, Hikota-Saga Reina, Maekawa Takaaki, Yamamura Takeshi, Kobayashi Ayako, Kobayashi Shinichi, Kimura Fumihiko
Abstract excerpt
Glucocorticoid (GC) therapy occasionally relieves tumor-related fever and promotes tumor reduction in patients with chronic myelomonocytic leukemia (CMML). A mutation analysis of 24 patients with CMML revealed the relationship of GC effectiveness, defined as a monocyte reduction of > 50% within 3 days of methylprednisolone administration, with the MEFV single-nucleotide variant (SNV) and CBL mutation....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.